Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk · Phase 3 · Completed · Enrollment 3731

NCT01272219

EudraCT 2008-001049-24

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

23.749.6
≥5%
10.633.1
≥10%
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)n/rn/rn/rn/r
Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)n/rn/rn/rn/r
Liraglutide Placebo, no Pre-diabetesn/rn/rn/rn/r
Liraglutide 3.0mg, Pre-diabetesn/rn/rn/rn/r
Liraglutide Placebo, Pre-diabetes23.7%10.6%n/rn/r
Liraglutide 3.0 mg (56-Week)49.6%33.1%n/rn/r

Not shown

  • Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68): endpoint not reported
  • Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68): endpoint not reported
  • Liraglutide Placebo, no Pre-diabetes: endpoint not reported
  • Liraglutide 3.0mg, Pre-diabetes: endpoint not reported